Board of Directors approves quarterly cash dividend of $0.39 per share
NEW YORK–(BUSINESS WIRE)–The board of directors of Pfizer Inc. (NYSE:PFE) declared a 39-cent first-quarter 2021 dividend on the company’s common stock, payable March 5, 2021, to holders of the Common Stock of record at the close of business on January 29, 2021. Pfizer increased the dividend over the fourth-quarter 2020 dividend by approximately 3 percent to 39 cents from 38 cents per share. The first-quarter 2021 cash dividend will be the 329th consecutive quarterly dividend paid by Pfizer.
The transaction to combine Upjohn with Mylan to form Viatris Inc. closed on November 16, 2020. It is expected that Viatris will begin paying a quarterly dividend in the second quarter of 2021, at which time Pfizer’s quarterly dividend will be reduced such that the combined dividend dollar amount received by Pfizer shareholders, based upon the combination of continued Pfizer ownership and approximately 0.124079 shares of Viatris which were granted for each Pfizer share in the spin-off, will equate to Pfizer’s dividend amount in effect immediately prior to the initiation of the Viatris dividend.
“Our commitment to returning capital to shareholders is strong and the dividend increase reflects our continued confidence in the business and in our scientific pipeline,” stated Dr. Albert Bourla, Pfizer Chairman and CEO. “It also reinforces that our focus on creating meaningful value for patients benefits all our stakeholders.”
Pfizer Inc.: Breakthroughs that change patients’ lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. (Read more…) Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
Pfizer Disclosure Notice
The information contained in this release is as of December 11, 2020. The Company assumes no obligation to update forward-looking statements contained in this release as a result of new information or future events or developments.
This release contains forward-looking information about the Company’s quarterly dividend in 2021 that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any drug applications may be filed for any of our product candidates in any jurisdiction; whether and when regulatory authorities in any jurisdictions where any applications are pending or may be submitted for our product candidates may approve any such applications, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy, and, if approved, whether they will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of our product candidates; the uncertainties inherent in business and financial planning, including, without limitation, risks related to Pfizer’s business and prospects, or any of our joint venture or business development counterparties’ business and prospects, adverse developments in Pfizer’s markets, or adverse developments in the U.S. or global capital markets, credit markets, regulatory environment or economies generally; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results,” as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
Contacts
Pfizer Media Contact:
Amy Rose
(212) 733-7410
Amy.Rose@pfizer.com
Pfizer Investor Contact:
Chuck Triano
(212) 733-3901
Charles.E.Triano@pfizer.com